Regulatory News: Eurofins Scientific SE (Paris:ERF): Revenues increased to a record level of €3,412m in H1 2022, up 4.3% vs. H1 2021, driven by good growth of Eurofins' Core Business (excluding
/PRNewswire/ Eurofins Viracor, a leader in infectious disease, immunology, and allergy testing, announced today that the Third Circuit of the Federal Court.
SAN DIEGO, July 6, 2022 /PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announcedthe acquisition of DiscoveryBioMed, a contract research organization (CRO) focused on developing novel human bioassays utilizing cells from diseased and normal human tissues. Eurofins Discovery acquired DiscoveryBioMed for its expertise in leveraging primary and immortalized human diseased and normal cells to develop novel, customized bioassays supporting clients from HTS to lead optimization. DiscoveryBioMed achieves this through its focus on biologically relevant cellular models for the renal, skin, taste, ophthalmic, liver, respiratory, oncology, and other therapeutic areas. The addition of DiscoveryBioMed supports Eurofins Discovery's strategy to have the most complete, highest quality portfolio of drug discovery services and products, and further strengthens its ability to support tr
/PRNewswire/ Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery,.